Risperidone extended release - Rovi

Drug Profile

Risperidone extended release - Rovi

Alternative Names: Risperidone-ISM®

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator Rovi
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Schizophrenia

Most Recent Events

  • 06 Mar 2017 Rovi's extended release Risperidone is still at phase II development stage for Schizophrenia in USA (IM)
  • 16 Feb 2017 Rovi plans the PRISMA-3 trial
  • 28 Jul 2016 Pharmacokinetics and adverse events data from a phase II trial in Schizophrenia released in Rovi First Half 2016 Financial Results
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top